New drug cocktail trial aims to tame tough tumors
NCT ID NCT01552434
First seen Nov 01, 2025 · Last updated May 02, 2026 · Updated 29 times
Summary
This early-phase trial tests the safety and best dose of two drugs (bevacizumab and temsirolimus) given alone or with a third drug (valproic acid or cetuximab) in people with advanced cancers or certain non-cancerous but progressive diseases. The goal is to find tolerable doses and see if these combinations can slow or stop tumor growth. About 155 adults with hard-to-treat cancers or conditions like Castleman disease are participating.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC UROTHELIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.